Latest Insider Transactions at Intra Cellular Therapies, Inc. (ITCI)
This section provides a real-time view of insider transactions for Intra Cellular Therapies, Inc. (ITCI). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Intra-Cellular Therapies, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Intra-Cellular Therapies, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 07
2023
|
Mark Neumann EVP, Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
55,300
+35.46%
|
$995,400
$18.59 P/Share
|
|
Jul 17
2023
|
Suresh K. Durgam EVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,842
-7.97%
|
$119,730
$65.0 P/Share
|
|
Jun 30
2023
|
Robert L Van Nostrand |
BUY
Grant, award, or other acquisition
|
Direct |
85
+0.89%
|
$5,355
$63.32 P/Share
|
|
Jun 30
2023
|
Rory B Riggs |
BUY
Grant, award, or other acquisition
|
Direct |
279
+0.35%
|
$17,577
$63.32 P/Share
|
|
Jun 14
2023
|
Lawrence J. Hineline SVP of Finance, CFO |
SELL
Open market or private sale
|
Direct |
81,854
-78.09%
|
$5,238,656
$64.24 P/Share
|
|
Jun 14
2023
|
Lawrence J. Hineline SVP of Finance, CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
81,854
+24.03%
|
$3,437,868
$42.8 P/Share
|
|
Apr 17
2023
|
Robert L Van Nostrand |
SELL
Open market or private sale
|
Direct |
10,000
-51.69%
|
$630,000
$63.0 P/Share
|
|
Apr 17
2023
|
Robert L Van Nostrand |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+34.08%
|
$130,000
$13.05 P/Share
|
|
Mar 31
2023
|
Rory B Riggs |
BUY
Grant, award, or other acquisition
|
Direct |
313
+0.4%
|
$16,902
$54.15 P/Share
|
|
Mar 31
2023
|
Robert L Van Nostrand |
BUY
Grant, award, or other acquisition
|
Direct |
95
+1.01%
|
$5,130
$54.15 P/Share
|
|
Mar 28
2023
|
Mark Neumann EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
15,604
-13.62%
|
$842,616
$54.43 P/Share
|
|
Mar 13
2023
|
Mark Neumann EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
3,758
-2.92%
|
$165,352
$44.57 P/Share
|
|
Mar 13
2023
|
Suresh K. Durgam EVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
7,344
-12.23%
|
$323,136
$44.69 P/Share
|
|
Mar 13
2023
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+1.71%
|
$60,000
$3.26 P/Share
|
|
Mar 13
2023
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
20,565
-0.89%
|
$904,860
$44.57 P/Share
|
|
Mar 13
2023
|
Lawrence J. Hineline SVP of Finance, CFO |
SELL
Open market or private sale
|
Direct |
5,582
-97.69%
|
$245,608
$44.56 P/Share
|
|
Mar 13
2023
|
Michael Halstead EVP and General Counsel |
SELL
Open market or private sale
|
Direct |
7,344
-96.76%
|
$323,136
$44.57 P/Share
|
|
Mar 10
2023
|
Mark Neumann EVP, Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,344
+10.19%
|
-
|
|
Mar 10
2023
|
Mark Neumann EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
8,550
-6.64%
|
$367,650
$43.12 P/Share
|
|
Mar 10
2023
|
Suresh K. Durgam EVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,344
+19.43%
|
-
|
|
Mar 10
2023
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
20,565
+1.76%
|
-
|
|
Mar 10
2023
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
41,770
-1.79%
|
$1,754,340
$42.89 P/Share
|
|
Mar 10
2023
|
Lawrence J. Hineline SVP of Finance, CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,582
+50.0%
|
-
|
|
Mar 10
2023
|
Lawrence J. Hineline SVP of Finance, CFO |
SELL
Open market or private sale
|
Direct |
15,663
-91.38%
|
$657,846
$42.84 P/Share
|
|
Mar 10
2023
|
Michael Halstead EVP and General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
7,344
+50.0%
|
-
|
|
Mar 10
2023
|
Michael Halstead EVP and General Counsel |
SELL
Open market or private sale
|
Direct |
16,708
-92.52%
|
$701,736
$42.86 P/Share
|
|
Mar 09
2023
|
Mark Neumann EVP, Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,708
+20.22%
|
-
|
|
Mar 09
2023
|
Sharon Mates Chairman and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
41,770
+3.44%
|
-
|
|
Mar 09
2023
|
Lawrence J. Hineline SVP of Finance, CFO |
BUY
Grant, award, or other acquisition
|
Direct |
15,663
+50.0%
|
-
|
|
Mar 09
2023
|
Michael Halstead EVP and General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
16,708
+50.0%
|
-
|
|
Mar 01
2023
|
Mark Neumann EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
7,241
-12.83%
|
$362,050
$50.01 P/Share
|
|
Feb 24
2023
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+2.59%
|
$90,000
$3.26 P/Share
|
|
Feb 24
2023
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
22,590
-2.01%
|
$1,061,730
$47.03 P/Share
|
|
Feb 24
2023
|
Lawrence J. Hineline SVP of Finance, CFO |
SELL
Open market or private sale
|
Direct |
7,455
-100.0%
|
$350,385
$47.03 P/Share
|
|
Feb 24
2023
|
Michael Halstead EVP and General Counsel |
SELL
Open market or private sale
|
Direct |
7,906
-100.0%
|
$371,582
$47.03 P/Share
|
|
Feb 24
2023
|
Suresh K. Durgam EVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
7,906
-25.5%
|
$371,582
$47.14 P/Share
|
|
Feb 24
2023
|
Mark Neumann EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
4,046
-6.69%
|
$190,162
$47.12 P/Share
|
|
Feb 23
2023
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
22,590
+1.97%
|
-
|
|
Feb 23
2023
|
Lawrence J. Hineline SVP of Finance, CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
7,455
+50.0%
|
-
|
|
Feb 23
2023
|
Michael Halstead EVP and General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
7,906
+50.0%
|
-
|
|
Feb 23
2023
|
Suresh K. Durgam EVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,906
+20.32%
|
-
|
|
Feb 23
2023
|
Mark Neumann EVP, Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,906
+11.56%
|
-
|
|
Feb 21
2023
|
Suresh K. Durgam EVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
8,354
-7.03%
|
$392,638
$48.0 P/Share
|
|
Feb 21
2023
|
Mark Neumann EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
3,898
-2.33%
|
$183,206
$47.62 P/Share
|
|
Feb 21
2023
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
27,848
-0.62%
|
$1,336,704
$48.05 P/Share
|
|
Feb 21
2023
|
Lawrence J. Hineline SVP of Finance, CFO |
SELL
Open market or private sale
|
Direct |
10,443
-79.49%
|
$501,264
$48.05 P/Share
|
|
Feb 21
2023
|
Michael Halstead EVP and General Counsel |
SELL
Open market or private sale
|
Direct |
11,139
-77.5%
|
$534,672
$48.02 P/Share
|
|
Feb 18
2023
|
Suresh K. Durgam EVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,354
+20.98%
|
-
|
|
Feb 18
2023
|
Mark Neumann EVP, Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,139
+16.47%
|
-
|
|
Feb 18
2023
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
27,848
+2.41%
|
-
|